Lacroix, André http://orcid.org/0000-0003-4137-3025
Gu, Feng
Schopohl, Jochen
Kandra, Albert
Pedroncelli, Alberto M.
Jin, Lixian
Pivonello, Rosario
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
https://doi.org/10.1007/s11102-019-01021-2
Article History
First Online: 24 December 2019
Compliance with ethical standards
:
: AL has received funding from Novartis Pharmaceuticals Corporation to conduct clinical studies with pasireotide SC and osilodrostat (LCI699) in Cushing’s disease and served occasionally as a consultant, an advisory group member, or a speaker for Novartis, EMD Serono, and Ipsen. FG has served as a consultant, an advisory group member, an investigator, and a speaker for Novartis and Ipsen. JS has served as a lecturer, a researcher, and an advisory group member for Novartis, Ipsen and Pfizer. AK and AMP are employees of Novartis Pharma AG and hold stock options. LJ was employed by Novartis at the time of writing this manuscript but is currently employed by Bristol-Myers Squibb. RP has served as an investigator, a researcher, a consultant, and a speaker for Novartis, Viropharma, Shire, HRA Pharma, and Ipsen.
: All procedures performed in studies involving human participants were in accordance with the protocol, the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, applicable local regulations (including European Directive 2001/20/EC and US Code of Federal Regulations Title 21), and the 1964 Helsinki declaration and its later amendments. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.